NOZINAN DIN 01927728
Status: Cancelled Post Market
Holder: SANOFI-AVENTIS CANADA INC
Health Canada record
| Active ingredient(s) | METHOTRIMEPRAZINE (METHOTRIMEPRAZINE HYDROCHLORIDE) 5 MG |
|---|---|
| Dosage form | Solution |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | N05AA02 LEVOMEPROMAZINE |
| Original market date | 31-Dec-1966 |
| Current status date | 28-Jul-2006 |
| Source | Health Canada DPD |
Establishment licence of the holder
sanofi-aventis Canada Inc. — licence 101470, currently licensed, last inspection rating C (2026-02-17).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing METHOTRIMEPRAZINE (METHOTRIMEPRAZINE HYDROCHLORIDE)
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 01927698 | NOZINAN | NEURAXPHARM ARZNEIMITTEL GMBH | Solution | METHOTRIMEPRAZINE (METHOTRIMEPRAZINE HYDROCHLORIDE) 25 MG | Marketed |
| 01927701 | NOZINAN | AVENTIS PHARMA INC | Liquid; Drops | METHOTRIMEPRAZINE (METHOTRIMEPRAZINE HYDROCHLORIDE) 40 MG | Cancelled Post Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 7952 | 2006-05-11 | New Drug Submission (NDS) | MANUFACTURER NAME CHANGE |
| 1283 | 2000-11-14 | New Drug Submission (NDS) |